Why PV Mandates Matter in 2026?
Pharma manufacturers are rapidly launching their products across borders, directly intensifying the burden on safety monitoring. On the other hand, to enable quick signal detection, the PV processes are closely integrated with emerging technologies such as Artificial Intelligence, digital reporting platforms, and real-world evidence (RWE), which are recommended for inclusion in regulatory frameworks. The shift for this rapid safety intelligence requires proactive approaches rather than reactive compliance. Hence, learning about the global landscape of mandatory Pharmacovigilance is critical. Here, we give you a few key Pharmacovigilance (PV) mandates to look into in 2026 across key global regions.
What’s Expected to Change in the EU Pharmacovigilance (PV) Landscape?
The EU remains the torchbearer of PV regulation. As you may know, in July 2025, the European Commission (EC) adopted Implementing Regulation (EU) 2025/1466. A significant amendment to existing legislation is scheduled to come into practice on 12th of February 2026.
It is expected that, with this change, there will be greater emphasis on quality, transparency, and standardized reporting to streamline regulatory decisions across all EU member states.
Key Considerations:
- The burden of documentation will be reduced in the Pharmacovigilance System Master File (PSMF). The new legislation demands only critical deviations from the standard PV procedures to be documented in the PSMF.
- Subcontractors’ safety responsibilities should be explicitly defined in the contracts. The responsibilities might range from data exchange requirements to audit rights. In a way, it gives strict control over third parties.
- Market Authorization Holders (MAHs) will need to continuously monitor data in EudraVigilance to detect signals promptly. They are entitled to quickly validate the signals.
- Periodic safety update reports (PSURs) will be required to report on risk management effectiveness, and post-authorisation safety studies (PASS) must be electronically registered before data collection.
What’s Expected to Change in the US Pharmacovigilance Landscape?
In the United States, the FDA’s regulatory framework for pharmacovigilance remains unchanged, and it continues to refine the Good Pharmacovigilance Practices (GVP) in step with new innovations and patient safety. The health authority continues to oversee PV activities through previously established post-marketing reporting regulations. It also includes Title 21 of the Code of Federal Regulations (CFR). However, in 2026, there will be greater emphasis on electronic reporting and structured safety data. For serious adverse events, expedited timelines will apply.
Key Considerations:
- Electronic submission of serious adverse event reports to FAERS (FDA database) will be mandatory.
- Safety signal identification and communication will heavily depend on the use of real-world data and analytics.
- Regulations will closely align with ICH guidance.
What’s Expected to Change in the Brazilian Pharmacovigilance (PV) Landscape?
ANVISA, the Brazilian health authority, introduced a new pharmacovigilance regulation – RDC No. 967/25. It becomes mandatory in March 2026. The new regulation aims to match international data standards.
Key Considerations:
- For submitting adverse drug reaction (ADR) reports, the marketing authorization holders (MAHs) should mandatorily use VigiMed. They should adhere to it in accordance with the E2B(R3) data exchange standard.
- It is expected that MAHs should leverage the established MedDRA coding standards. They should aim to enhance consistency and enable global comparability.
What is expected to change in the Indian Pharmacovigilance (PV) landscape?
The Pharmacovigilance Programme of India (PvPI) guides India’s pharmacovigilance infrastructure. The PvPI works under the Central Drugs Standard Control Organization (CDSCO) and emphasizes:
- Supporting signal detection and safety assessments through robust National ADR reporting systems
- Anticipated to plan and train risk management, aligning with the WHO requirements for national PV systems
What is expected to change in the Asia-Pacific Pharmacovigilance (PV) Landscape?
Across Asia Pacific, other regulators, such as Japan’s PMDA and Australia’s TGA, maintain their own reporting standards and risk-based oversight, often aligned with ICH GVP principles, underscoring global harmonization.
What is expected to change in the Middle East and African Pharmacovigilance (PV) Landscape?
- Regulators in Africa are aiming to collaborate with regional bodies such as AVAREF. The goal is to harmonize safety monitoring and update PV requirements for imported products.
- SFDA of Saudi Arabia and SAHPRA of South Africa mandate strict timelines for electronic reporting and post-market surveillance.
What Should Pharma Companies Do for Pharmacovigilance (PV) Compliance in 2026?
- Quickly review and update PV systems to adhere to EU 2025/1466, and ANVISA RDC 967/25
- Practice implementing robust signal management processes for timely validation and reporting
- For terminology and data exchange, look up and adopt MedDRA and ISO IDMP
- Train local and global PV teams on the upcoming changes to the reporting systems
- Focus on AI-assisted signal detection, automated case processing to sustain the growing data volumes
For accurate information on global Pharmacovigilance (PV) regulatory updates and best practices for compliance, reach out to a trusted partner like VigilareBP.